India, Oct. 9 -- Thursday, TRexBio announced the pricing of its initial public offering of 8.33 million shares at $14.00 per share, raising approximately $116.7 million in gross proceeds.
The company's shares are expected to begin trading on the Nasdaq Global Select Market under the ticker TRXB.
TRexBio is a clinical-stage biotechnology company developing therapies the target regulatory T cells (Tregs) to treat autoimmune and inflammatory diseases.
The underwriters have been granted a 30-day option to purchase up to 1.25 million additional shares at the IPO price.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....